Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir on June 16, 2026. This achievement marks the first oral antiviral medication approved for post-exposure prophylaxis of COVID-19 globally, representing a significant advancement that accelerates the company’s global expansion efforts.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-06-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4507-20260601-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir on June 16, 2026. This achievement marks the first oral antiviral medication approved for post-exposure prophylaxis of COVID-19 globally, representing a significant advancement that accelerates the company's global expansion efforts.","jir_summary":"### Overview of Financial Performance\nShionogi & Co., Ltd. announced that its US subsidiary received FDA approval on June 16, 2026, for the indication of post-exposure prophylaxis of COVID-19 with the anti-SARS-CoV-2 drug ensitrelvir. Based on positive results from the global Phase 3 post-exposure prevention trial (SCORPIO-PEP), this milestone signifies the world's first approval for an oral antiviral medication for post-exposure prophylaxis. The drug reduces the risk of developing COVID-19 by 67% up to 10 days after administration, with a favorable safety profile. Moving forward, the company aims to contribute to comprehensive infectious disease care as part of infection control measures and continues to expand globally.\n\n### Future Outlook and Corporate Activities\nShionogi & Co., Ltd. considers overcoming infectious disease threats a key management goal and is promoting R&D in infectious diseases. The FDA approval enables the company to expand sales in overseas markets such as the United States, while also pursuing license agreements to improve access for low- and middle-income countries. These developments are already incorporated into the consolidated earnings forecast for the fiscal year ending March 2027, and the company is expected to play an important role in infectious disease countermeasures moving forward.","jir_financial_highlights":"Approval Date: 2026-06-16 (Unknown)\nNumber of FDA Approvals Achieved: 1 (Unknown)","jir_category":"","jir_hashtags":"#ShionogiPharmaceutical, #IR, #JapanStocks","jir_key_figures":"Approval Date: 2026-06-16\nNumber of FDA Approvals Achieved: 1\nReduction in COVID-19 development risk within 10 days of administration: 67%","jir_meta_title":"\u3010Shionogi & Co., Ltd.\u3011FDA Approval for COVID-19 Post-Exposure Prophylaxis Drug | May 2026","jir_meta_description":"Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir in June 2026. This marks a significant step toward global expansion and infectious disease prevention.","jir_og_title":"\u3010Shionogi & Co., Ltd.\u3011FDA Approval for COVID-19 Post-Exposure Prophylaxis Drug | May 2026","jir_og_description":"Shionogi & Co., Ltd. achieved FDA approval for the anti-SARS-CoV-2 drug in June 2026. A crucial step for future expansion and infectious disease countermeasures.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-55718","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n